Fradafiban hydrochloride

Cat. No.: HY-101720A

Molecular Formula: $C_{20}H_{22}ClN_3O_4$

Molecular Weight: 403.86

Target: Integrin

Pathway: Cytoskeleton

Storage: 4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



BIOLOGICAL ACTIVITY

Description	Fradafiban (BIBU-52) hydrochloride is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a K_d value of 148 nM.
IC_{50} & Target	Kd: 148 nM (human platelet GP IIb/IIIa complex)[1]
In Vitro	Fradafiban hydrochloride is a nonpeptide mimetic of the arginine-glycine-aspartic acid recognition sequence. Fradafiban hydrochloride binds with high affinity and selectivity to the human platelet GP IIb/IIIa complex and potently inhibits human platelet aggregation in vitro. Fradafiban hydrochloride reversibly binds to the human platelet GP IIb/IIIa complex with a K_d value of 148 nM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Fradafiban hydrochloride has only very limited oral activity probably due to its high polarity and thus poor absorption after oral ingestion[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Müller TH, et al. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation. 1997 Aug 19;96(4):1130-8.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA